Stem Cell Assurance, MDwerks announce financing and marketing partnership

Download PDF Copy

Jan 21 2010

NewsGuard 100/100 Score

Stem Cell Assurance, Inc. (PK: SCLZ) and MDwerks, Inc. (OTC Bulletin Board: MDWK) announced today a financing and marketing partnership today wherein MDwerks, through it's Xeni Finance subsidiary, has provided the first tranche of financing to Stem Cell for the purchase of various medical devices from Cytori Therapeutics, Inc. In addition, MDwerks, through its subsidiary Digital Pen Applications, Inc. (DPA), will assist in marketing Stem Cell products and services to the health care and medical community initially in Florida. Stem Cell also has expansion plans for New York, New Jersey, Texas and California.

SOURCE Stem Cell Assurance, Inc.

Posted in:

Tags: B Cell, Cell, Health Care, Medical Devices, Nursing, Stem Cells, T-Cell, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Mapping human biology: Human Cell Atlas leads a new era in precision medicine

Mapping human biology: Human Cell Atlas leads a new era in precision medicine

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

Researchers discover mechanism affecting splicing process in retinal cells

Researchers discover mechanism affecting splicing process in retinal cells

Researchers discover how mutations disrupt protein splicing and cause disease

Researchers discover how mutations disrupt protein splicing and cause disease

Barcoding small extracellular vesicles with new CRISPR-based system

Barcoding small extracellular vesicles with new CRISPR-based system

SCimilarity revolutionizes single-cell data analysis with rapid cross-tissue comparisons

SCimilarity revolutionizes single-cell data analysis with rapid cross-tissue comparisons

Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Researchers reveal cellular foundations of functional brain networks in humans